

MERRIMACK PHARMACEUTICALS INC  
 Form 3  
 April 10, 2017

**FORM 3** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Drummond Daryl C (Last) (First) (Middle)  C/O MERRIMACK PHARMACEUTICALS, INC., Â ONE KENDALL SQUARE, SUITE B7201 (Street)  CAMBRIDGE, Â MA Â 02139 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/31/2017	3. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Head of Research	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	---	--	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	92,420	D	Â
Common Stock	9,311	I	By Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	Â <u>(1)</u>	02/01/2020	Common Stock	80,000	\$ 2.12	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	10/15/2020	Common Stock	27,500	\$ 2.69	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	05/03/2021	Common Stock	20,000	\$ 5.54	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	08/22/2022	Common Stock	14,100	\$ 7.53	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	03/11/2023	Common Stock	50,000	\$ 6.35	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	02/10/2024	Common Stock	30,000	\$ 5.02	D	Â
Stock Option (right to buy)	Â <u>(2)</u>	02/08/2025	Common Stock	32,500	\$ 9.08	D	Â
Stock Option (right to buy)	Â <u>(3)</u>	02/07/2026	Common Stock	42,000	\$ 5.42	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	07/03/2017	Common Stock	4,097	\$ 2.69	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	07/03/2017	Common Stock	900	\$ 5.54	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,400	\$ 7.53	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,700	\$ 6.35	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,796	\$ 5.02	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	599	\$ 9.08	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	333	\$ 5.42	I	By Wife

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director    10% Owner    Officer    Other

Reporting Owners

Drummond Daryl C  
C/O MERRIMACK PHARMACEUTICALS, INC.  
ONE KENDALL SQUARE, SUITE B7201  
CAMBRIDGE, MA 02139

Â                      Â                      Â Head of  
Research                      Â

## Signatures

/s/ Brian J. Kickham,  
attorney-in-fact

04/10/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option is fully vested.
- (2) This option vested as to 1/12th of the total number of shares on 5/9/15 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/9/18.
- (3) This option vested as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.